These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Effect of everolimus on polycystic liver volume in autosomal dominant polycystic kidney disease. Zschiedrich S; Budde K; Walz G Clin Exp Nephrol; 2015 Aug; 19(4):757-8. PubMed ID: 25424440 [No Abstract] [Full Text] [Related]
10. Cyst infection in autosomal dominant polycystic kidney disease: penetration of meropenem into infected cysts. Hamanoue S; Suwabe T; Ubara Y; Kikuchi K; Hazue R; Mise K; Ueno T; Takaichi K; Matsumoto K; Morita K BMC Nephrol; 2018 Oct; 19(1):272. PubMed ID: 30340529 [TBL] [Abstract][Full Text] [Related]
11. Uncommon cause of chest pain in a renal transplantation patient with autosomal dominant polycystic kidney disease: a case report. Rodrigues L; Neves M; Machado S; Sá H; Macário F; Alves R; Mota A; Campos M Transplant Proc; 2012 Oct; 44(8):2507-9. PubMed ID: 23026633 [TBL] [Abstract][Full Text] [Related]
12. Successfully treated Escherichia coli-induced emphysematous cyst infection with combination of intravenous antibiotics and intracystic antibiotics irrigation in a patient with autosomal dominant polycystic kidney disease. Kim H; Park HC; Lee S; Lee J; Cho C; Kim DK; Hwang YH; Oh KH; Ahn C J Korean Med Sci; 2013 Jun; 28(6):955-8. PubMed ID: 23772165 [TBL] [Abstract][Full Text] [Related]
13. Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease. Peces R; Cuesta-López E; Peces C; Pérez-Dueñas V; Vega-Cabrera C; Selgas R Int Urol Nephrol; 2011 Jun; 43(2):565-9. PubMed ID: 20449653 [TBL] [Abstract][Full Text] [Related]
14. Rupture of an infected liver cyst into the pericardium in a kidney transplant recipient with polycystic kidney disease. Egbuna O; Johnson S; Pavlakis M Am J Kidney Dis; 2007 Jun; 49(6):851-3. PubMed ID: 17533028 [TBL] [Abstract][Full Text] [Related]
15. [Infected hepatic cyst in ADPKD patient in peritoneal dialysis]. Peruzzu N; Borrelli S; Netti A; De Stefano T; Vita C; Sabatino M; Salzano M; Conte G; De Nicola L; Minutolo R; Garofalo C G Ital Nefrol; 2019 Apr; 36(2):. PubMed ID: 30983178 [TBL] [Abstract][Full Text] [Related]
16. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease. van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH; Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403 [TBL] [Abstract][Full Text] [Related]
17. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108 [TBL] [Abstract][Full Text] [Related]